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Introduction
in March 2008, around 100 young scientists met at the Spanish 
national cancer centre (cnio) in Madrid, Spain, to share their 
results with one another and a few invited senior scientists from 
their fields. the workshop was organized by eight foreign students 
on the oncotrain programme—supported by the Vi European 
Framework—who are undertaking their phDs at the cnio in the 
fields of cancer research. as such, the meeting reflected the areas 
in which the organizers are working, namely cell cycle, cancer 
genetics, drug discovery and cancer stem cells (cScs). posters and 
oral presentations were grouped around these areas, with two key 
lectures and a few selected oral presentations per session. 
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Cycling to cancer: cell cycling and cell division
cancer is ultimately a cell-cycle disease as most tumours occur 
owing to one or more errors that derail the cell-cycle machinery. Such 
defects can affect either components of the cell cycle itself—includ-
ing checkpoint mechanisms—or elements of upstream signalling cas-
cades, which should ultimately converge to trigger cell-cycle events 
(Malumbres & carnero, 2003). these cell-cycle aberrations not only 
damage the regulation of the g1-to-S phase, but also alter the mitotic 
checkpoint, which gives rise to the chromosomal alterations observed 
in most human tumours.
E. nigg (Martinsried, germany) reviewed the mitotic check-
point and then focused our attention on his recent work with plK1 
and plK1-interacting checkpoint helicase (picH). plK1 is a crucial 
regulator of mitotic progression and cell division in eukaryotes. it is 
highly expressed in tumour cells and is considered to be a potential 
target for cancer therapy. By using zK-thiazolidinone (tal), which is 
a small-molecule inhibitor of mammalian plK1, nigg has studied the 
role of plK1 in sister-chromatid separation, centrosome maturation 
and spindle assembly, and has shown that plK1 activity is essential 
for cleavage-furrow formation and regression, leading to success-
ful cytokinesis (Santamaria et  al, 2007). picH is a member of the 
SW1/SnF2 family of Dna-dependent atpases and is an essential 
component of the spindle-assembly checkpoint. it has been shown 
to localize to kinetochores, inner centromeres and the thin threads 
that connect separating chromosomes during anaphase (Baumann 
et  al, 2007). picH associates with centromeric chromatin during 
anaphase, and the analysis of picH-positive anaphase threads has 
shown that they comprise mainly alphoid centromere Dna. Most 
picH-positive threads evolve from inner centromeres, as these stretch 
in response to tension, suggesting that picH might be a sensor of 
tension during chromosome separation (Baumann et al, 2007).
M. Malumbres (Madrid, Spain) discussed the work of his group 
with the apc/c, which is a ubiquitin ligase that targets mitotic sub-
strates for degradation in complex with either cDc20 or cDH1 
co-factors. the specificity of the complex for certain substrates is 
determined by the cofactor involved, and the Malumbres group 
has studied this specificity by generating conditional knockout 
(Ko) models of both proteins in mice. their work has shown that 
cDc20 is essential for embryo development, and that its absence 
arrests development at the two-cell embryo stage at the point of 
mitosis, perhaps owing to a large accumulation of cyclin B (Fig 1). 
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Similarly, CDH1-KO embryos die after progression to embryonic 
day 10.5. the CDH1-KO  embryos showed decreased haemato-
poiesis and important defects in maternal–embryo blood exchange 
in the placenta. cDH1 is important for the endoreduplication of 
cells. the absence of cDH1 in the placenta and embryo reduced the 
size of the nucleus of placenta trophoblast giant cells; by contrast, 
the specific ablation of cDH1 in the embryo rescued the pheno-
type and the embryos survived, although the mice died shortly after 
birth. in cDH1-null cells, most apc/cDH1 targets are upregulated, 
which results in inefficient Dna replication and genomic instabil-
ity. it is possible that these defects in Dna replication and genomic 
instability explain the reduced tumour formation after carcinogenic 
treatment in mice with only one allele of Cdh1.
How could genetics explain cancer?
cancer is a genetic disease in which the evolution from normal to 
cancerous tissue is driven by genetic—including cytogenetic—or 
epigenetic changes. nowadays, new genetic and cytogenetic 
tools allow mass analysis and identification of candidate regions 
and genes that are involved in disease. However, these altera-
tions do not affect all individuals equally and genetic background 
is important. these tools also allow for the identification of single- 
nucleotide polymorphisms (Snps) that confer a susceptibility to 
cancer. the identification of these Snps and the way in which they 
interact is essential to understanding cancer risks in some individu-
als. J. Benitez (Madrid, Spain) presented data to show how his group 
distinguishes between low-penetrance and moderate-penetrance 
genes, which confer susceptibility to sporadic cancer, and high-
penetrance genes, which are responsible for hereditary cancer. His 
group has identified a 1-Mb region of chromosome 21q that prob-
ably contains a high-penetrance gene member of one of the non-
Brca1/Brca2 families. the Benitez group also found two Snps of 
the vitamin D receptor that is associated with differentiation grade 
and tumour aggressiveness in non-related sporadic breast cancer.
comparative genomic hybridization (cgH) was developed to detect 
chromosomal copy-number changes on a genome-wide scale. using 
arrays to perform cgH (cgHa) allows the detection of chromosome 
copy numbers at a high-resolution scale (ijssel & ylstra, 2007; ylstra 
et al, 2006). By using cgHa, B. ylstra (amsterdam, the netherlands) 
and collaborators found small chromosomal regions responsible for 
many tumour phenotypes ( Jong et al, 2007; Buffart et al, 2007; paterson 
et al, 2007). in an attempt to identify novel non-small-cell lung cancer 
(nSclc)-related genes, they performed genome-wide screening of 
chromosome copy number in stage i and ii tumours. they identified a 
deletion on 14q32-33 that correlated with increased survival. HSp90 
resides in that region, and low revels of HSp90 expression were cor-
related with increased survival (gallegos ruiz et al, 2008). ylstra also 
presented chromosomal alterations that allow differentiation between 
HpV16-induced and environmental carcinogenesis-induced head 
and neck squamous-cell carcinoma (HnScc). Four regions showed 
differences between HpV16-positive and HpV16-negative tumours, 
suggesting that these regions were involved in the initial stages of tumori- 
genesis (Smeets et al, 2006). Seven other chromosomal regions have 
common alterations in both types of tumour, suggesting involvement 
in later stages of HnScc development.
a collaboration between p. asero (catania, italy) and t. Visakorpi 
(tampere, Finland) has resulted in the identification of target genes for 
the common 1p amplification found in bladder cancer. using cgH, 
they have narrowed down the location of the amplification to a 1-Mb 
region between 1p21-22 and 1p35-36. asero and Visakorpi suggested 
that the increased levels of expression of rpl5, acid82K, FlJ13150, 
cgi100, galE and lypla2 associated with the cancer are due to their 
roles as putative oncogenes. a.E. rodriguez (Salamanca, Spain) identi-
fied genomic abnormalities in B-cell chronic leukaemia (ccl) by cgH 
(gains of 13q, 17p, 11q and 12q). With respect to the 12q gain, his 
group initially identified it as a minimal 12q12-q24 gain, determined 
the genes comprised within this region and evaluated their expres-
sion in the transcriptome of samples from ccl patients. they found 
increased expression of 144 genes associated with ccl, of which 92 
were located in the 12q12-q24 region, confirming that chromosomal 
gains or losses might reflect the imbalance of transcription found 
in tumour cells, as the chromosomal changes paralleled the expres-
sion changes of genes within the region (rodriguez et  al, 2007). 
g. gundrem (Barcelona, Spain) presented an improved and extend-
able database that integrates microarray-expression data and cgH 
arrays in specific tumour types to allow transcriptomic, large-scale 
genomic data and somatic mutation data analyses (www.intogen.org).
M. Scatolini (Valenta, italy) presented the results of a trans-
criptomic analysis of the various stages of melanoma progression. Her 
comparison of the signatures of the intermediate steps of the process 
showed that notch1 pathway deregulation seems to be essential in 
the transition between the common nevi and primary radial growth-
phase melanomas. the transition between these lateral and vertical 
growth-phase melanomas is characterized by the alteration of Wnt3, 
MapK and aKt pathways. interestingly, dysplastic nevi do not seem 
to be an intermediate step in the nevo–melanoma transition.
Glossary
ABL1 v-abl Abelson murine leukaemia viral oncogene homologue 1
ALK anaplastic lymphoma kinase
APC/C anaphase-promoting complex/cyclosome
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide   
 formyltransferase
BRCA breast cancer susceptibility gene
CDC20 cell-division cycle 20
CDH1 CDC20 homologue 1
CHK1 checkpoint kinase 1
FOXO3a forkhead box O3a
HIV human immunodeficiency virus
HPV16 human papillomavirus 16
HSP90 Heat-shock protein 90
IL-3 interleukin-3
LYPLA2 lysophospholipase II
MAPK mitogen-activated protein kinase
miRNAs microRNAs
MMP matrix metalloproteinase
MT1 membrane type 1
OCT4 octamer-binding transcription factor 4
PEDF pigment epithelium-derived factor
PI(3)K phosphatidylinositol-3-kinase
PLK1 Polo-like kinase 1
RAI retinoic acid-inducible
REV  regulator of virion expression
RPL5 ribosomal protein L5
STAT5  signal transducer and activator of transcription 5
SNF2 sucrose nonfermentable 2
SW1 switch 1
WNT3 wingless-type MMTV integration site family member 3
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Surprisingly, only a few presentations discussed mirnas. the stud-
ies presented by M.J. Bueno (Madrid, Spain) and a.B. Martinez-cruz 
(Madrid, Spain) were of note. Bueno used a genetic analysis of mouse 
tumours to identify mirnas involved in tumorigenesis, and showed 
that the genetic and epigenetic silencing of mir-203 might enhance 
aBl1 and Bcr-aBl1 oncogene expression in haematological malig-
nancies (Bueno et al, 2008). in fact, mir-203 functions as a tumour-
suppressor gene, and its silencing by promoter hypermethylation is 
involved in lymphoid and myeloid malignancies. Martinez-cruz 
compared the deregulation of mirnas in various mouse models dis-
playing distinct susceptibility to spontaneous epithelial tumours. the 
differential pattern of mirna expression allowed the identification 
of mirnas that were possibly responsible for such susceptibility and 
could be used to predict various tumour characteristics in the future. 
it seems likely that the identification of mirnas that are associated 
with each genetic or epigenetic alteration, the analysis of the behav-
iour of different mirnas in tumours, and the role of each mirna in 
downregulating specific targets will constitute important research 
topics in cancer genetics.
Structures and drug development
p. Workman (london, uK) comprehensively introduced the proc-
ess of drug discovery. to illustrate each point, Workman explored in 
detail the process that led to the discovery and development of HSp90 
inhibitors (for a review, see Workman, 2003, 2004; McDonald et al, 
2006). linking drug discovery with the mitotic checkpoint, M. zajac 
(Madrid, Spain) and B. Martínez-Delgado (Madrid, Spain) showed 
that Brca1 mediates the g2/M transition mainly through cHK1 
when treated with the HSp90 inhibitor 17aag. on treatment with 
the drug, the cells arrested at the g2/M phase and entered aberrant 
mitosis in a Brca1-dependent manner. a failure to arrest the cells at 
or before mitosis resulted in the formation of micronucleated cells, 
the aberrant segregation of chromosomes, microtubule misalignment 
and multicentrosomes, eventually leading to mitotic catastrophe and 
cell death.
J. Bravo (Madrid, Spain) reviewed the process of drug discovery 
from a structural point of view and explained how developing the 
crystal structure of any given target could help in the drug-discovery 
process. g. Bardenes (Valencia, Spain) presented an approach to 
drug discovery using protein–protein interaction inhibitors through 
structure-based drug design. in addition, Bardenes reported on 
some work that aimed to identify inhibitors of heparanase and 
Mt1-MMp—enzymes that degrade extracellular matrix compo-
nents, which are increased in some tumours—by using nuclear 
magnetic resonance (nMr). F.E. Boccalatte (torino, italy) pre-
sented the results from a functional phosphoproteomic analy-
sis of anaplastic large-cell lymphoma (alcl), and showed that 
alK-mediated atic phosphorylation enhances atic enzymatic 
activity, thereby hampering methotrexate-mediated transformilase- 
activity inhibition, and suggesting alK as a new therapeutic target 
for alcl, in combination with methotrexate. S. numanoglu (izmir, 
turkey) explored the effect of hyperthermia in doxorubicin-treated 
human breast carcinoma cells. Hyperthermia causes free radicals 
that induce Dna breaks, mutations and apoptosis, and, its combi-
nation with a topoisomerase i inhibitor as doxorubicin, increases 
its cytotoxic activity.
Fig 1 | Embryonic lethality caused by the genetic ablation of the APC/C cofactors, CDC20 mutant or CDH1 in the mouse. Picture kindly provided by  
M. Malumbres (Spanish National Cancer Centre, Spain). APC/C, anaphase-promoting complex/cyclosome; CDC20, cell-division cycle 20; CDH1, CDC20 
homologue 1; E, embryonic day; P, postnatal stage.
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F. zanella (Madrid, Spain) presented interesting cell-based 
assays that were developed for the identification of new anti-
tumoral compounds. to identify small-molecule inhibitors of the 
pi(3)K pathway, a high-throughput cell-imaging assay was estab-
lished to monitor the nucleo-cytoplasmatic translocation of a 
FoXo3a–gFp (green fluorescent protein) fusion protein in tumour 
cells (zanella et al, 2008). another cell-based screening platform 
was developed to identify nuclear-export inhibitors and specific 
silencers of the nuclear-export machinery using a gFp-labelled 
rEV protein from HiV. this platform was also shown to be useful as 
a counter screen for pathway deconvolution (zanella et al, 2007). 
Finally, another system based on the genetically engineered il-3-
dependent Ba/F3 cells was shown. in these cells, deprivation of 
il-3 induces death, which can be overridden by the activation of 
the pi(3)K, raS or Stat5 pathways. on the basis of this informa-
tion, a dual fluorescence-based platform was generated to explore 
differential cell survival using multiparametric cell imaging 
(rosado et al, 2008), which allows the identification of selective 
inhibitors specific for pi3K (Fig 2).
as targeting cScs apparently holds some hope for improving 
anticancer therapies, r. Fernandez-alonso (leon, Spain) reported 
a cellular system to identify compounds with the ability to target 
cScs. using gFp under the control of the oct4 promoter, which 
was ectopically expressed into embryoid bodies, the investigators 
were able to regulate the levels of expression of gFp and to monitor 
the behaviour of the stem cells of the embryoid body. Fernandez-
alonso screened a chemical library of marine compounds and 
identified regulators of the expression of oct4. as oct4 is one of 
the crucial regulators of stem-cell self-renewal, therapies that regu-
late this protein are expected to have a direct effect on the response 
of the tumours.
The stem of cancer
the last session of the workshop was dedicated to cScs. the cur-
rent model of carcinogenesis describes the formation of a tumour 
by the sequential accumulation of mutations in oncogenes and 
tumour-suppressor genes. tumours are therefore formed from a 
heterogeneous population of cells, the members of which continue 
to acquire new mutations with the clones selectively amplified by 
pure Darwinian selection. the current hypothesis of cScs states 
that only a small and distinctive proportion of the cancer cells can 
propagate the tumour. the cScs constitute this small subpopulation 
of cancer cells, the members of which have characteristics that are 
normally associated with stem cells. the definition of a cSc does 
not necessarily imply its origin from a stem or progenitor cell, 
Fig 2 | Schematic overview of the BaFiso assay system. (A) Paired isogenic cell 
lines engineered to acquire interleukin 3 (IL-3)-autonomous growth through 
constitutive activation of AKT or STAT5 signalling. The two cell lines are 
individually tagged with either yellow or cyan fluorescent proteins. The deep-
red fluorescing agent DRAQ5 was used to perform automated segmentation 
of cell nuclei (red cells). (B) Isogenic cells were co-cultured and treated with 
compounds, and the change in the relative cell number was calculated by 
distinct fluorescence. (C) Image representative of the co-culture of isogenic 
BAF3 lines expressing distinct fluorescent markers. Image kindly supplied 
by W. Link (CNIO, Spain). RTK, receptor tyrosine kinase; STAT5, signal 
transducer and activator of transcription 5.
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although current trends to identify them are based on the hypoth-
esis that cScs express surface markers that are associated with 
immature cell types. the identification of correct cSc markers has 
become a central, almost circular, task: it is necessary to identify 
reliable markers of cScs to identify the subpopulation of cScs. 
M.a. Blasco (Madrid, Spain) explored the role of telomeres 
and telomerase in stem-cell biology. using confocal telomere 
quantitative-fluorescence in situ hybridization (telomapping), the 
Blasco laboratory has found gradients of telomere length within 
tissues, with the longest telomeres mapping to the known stem-
cell compartments. the cells with the longest telomeres behave 
as stem cells on treatment with mitogenic stimuli (Flores et  al, 
2008). therefore, relative telomere length can be used as a stem-
cell marker. telomeres shorten with age in various mouse stem-cell 
compartments, which parallels a decline in stem-cell functional-
ity, indicating that telomere loss might contribute to stem-cell 
dysfunction with age (Flores et al, 2008). the next step is the use 
of the telomapping technique to explore the presence and behav-
iour of cScs. in mice without telomerase activity (Terc–/– ), p53 is 
increased, and the combined absence of Terc and p53 restores 
the mobilization of stem cells. Blasco proposed a general model 
in which p53 controls the checkpoint preventing stem cells with 
crucially short telomeres to regenerate aged tissue; however, 
the absence of p53 allows stem cells to form tumours (Finkel 
et al, 2007; Matheu et al, 2007). therefore, telomere length is rate 
limiting for mouse aging, owing to an inability to restore aged/
damaged tissue. it seems possible that the increase in telomerase 
activity, which prevents the appearance of tumours, could increase 
the lifespan of mice. to address this issue, in collaboration with 
M. Serrano (Madrid, Spain), Blasco crossed mice with increased 
telomerase activity in the skin (K5-Tert) with mice carrying an extra 
copy of the p53, p16inK4a and p19arF loci (super-p53/INK4), 
which are known to be more resistant to cancer (garcia-cao et al, 
2002, 2006; Matheu et al, 2007). these mice showed decreased 
symptoms of ageing and increased cancer survival.
neurogenesis is known to occur in the specific niches of the 
adult mammalian brain; however, whether germinal centres exist 
in the neural crest-derived peripheral nervous system is unknown. 
r. pardal (Sevilla, Spain) and co-workers have discovered stem 
cells in the adult carotid body, which is an oxygen-sensing organ 
of the sympathoadrenal lineage that grows in chronic hypoxaemia. 
pardal showed that carotid body growth during hypoxia, and the 
production of new neuron-like glomus cells, results from the 
activation of a resident population of neural crest-derived progen-
itors. on returning to normoxia, the carotid body size is restored 
and approximately 50% of the carotid body glomus cell mass is 
replaced by the newly formed cells, indicating a notable regen-
erative power that is unusual in an adult neural tissue. In vivo and 
in vitro analyses indicate that carotid body stem cells self-renew 
and are multipotent. pardal also provided compelling evidence that 
glia-like type ii cells are the in vivo precursors of new glomus cells, 
and demonstrated that the newly formed glomus cells have the 
same complex neurochemical and electrophysiological properties 
as the in situ carotid body (pardal et al, 2007). Several other groups 
focused on the central nervous system to identify cScs and mark-
ers regulating their properties. using p73-KO mice, l. gonzalez-
cano (tenerife, Spain) showed that p73, which is a member of the 
p53 family, is a positive regulator of embryonic stem-cell renewal. 
B. ortensi (Milan, italy) studied the role of the Rai gene in cScs 
isolated from glioblastoma multiforme tumours. rai is a neuronal-
specific member of the family of the Shc-like adaptor proteins that 
functions as a neuroprotective factor in mature neurons by acti-
vating the pi(3)K pathway (Villanacci et al, 2008). rai levels are 
increased in progenitor cells but decreased in differentiating cells. 
rai promotes neurogenesis through the β-catenin pathway and is 
expressed specifically in glioblastoma multiforme tumours. it will 
be interesting to test the effect of silencing rai in tumours, as Rai–/– 
cells have impaired differentiation and no migration ability.
at the molecular level, the alteration of stem-cell renewal path-
ways and/or the inhibition of differentiation processes have been rec-
ognized as essential steps for the transformation of cScs. However, 
based on oncogene-induced plasticity, it has also been proposed that 
cScs could be the result of a de-differentiation process induced by 
the expression/inhibition of a specific combination of genes (rapp 
et al, 2008). given the large heterogeneity of tumours, it is possible 
for both hypotheses to be correct.
Finally, there is a theory that such cells persist in tumours as a dis-
tinct population, and cause relapse and metastasis by giving rise to 
new tumours. the development of specific therapies targeted at cScs 
holds hope for improving of the survival and quality of life of cancer 
patients, especially sufferers of metastatic disease. c. gil (albacete, 
Spain) and c. ramirez-castillejo (albacete, Spain) identified pEDF, 
which is a secreted factor that promotes the self-renewal of neural 
stem cells in vitro (ramirez-castillejo et al, 2006). treatment of differ-
ent cellular neuronal subpopulations reveals various susceptibilities to 
chemotherapy. combining standard chemotherapy with the carboxy-
terminal fragment of pEDF alters the response to treatments and could 
lead to new strategies to abolish cSc-derived resistance.
Concluding remarks
the oncotrain meeting could be seen as representing a small survey 
of the ‘temperature’ of various areas of cancer research. there was an 
emphasis on certain subjects—the regulation of the mitotic check-
point and the relevance of various genes to cancer, for example—
and it was clear that there is still much to be discovered. in addition, 
although the analysis of genetic and cytogenetic alterations on a 
massive scale is being applied to large numbers of samples in order 
to identify prognostic markers, more functional studies are neces-
sary. Finally, there is no doubt that a better understanding of cScs 
will lead to a new era of both basic and clinical cancer research, 
the reclassification of human tumours and the development of novel 
therapeutic strategies specifically targeting cSc.
all in all, this was an exciting and successful meeting, which 
was wonderfully organized by the oncotrain students with the help 
of the Scientific Events office of the cnio. this format should be 
repeated, because it brings together established and fresh scientific 
blood in a friendly, scientific environment that allows the students to 
discuss their work and exchange ideas.
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